Targeting antibacterial agents by using drug-carrying filamentous bacteriophages

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 6, 2006, Pages 2087-2097

  Yacoby, Iftach ^a   Shamis, Marina ^a   Bar, Hagit ^a   Shabat, Doron ^a   Benhar, Itai ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLORAMPHENICOL; CYTOTOXIC AGENT; DRUG CARRIER; PRODRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIOPHAGE; CELL SURFACE; DISSOCIATION; DNA MODIFICATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; DRUG TARGETING; FILAMENTOUS BACTERIOPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STAPHYLOCOCCUS AUREUS; STRUCTURE ANALYSIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHLORAMPHENICOL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEASIBILITY STUDIES; INOVIRUS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PRODRUGS; STAPHYLOCOCCUS AUREUS;

EID: 33744460747     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00169-06     Document Type: Article

References (46)

1. Azema, J., B. Guidetti, M. Malet-Martino, R. Martino, and C. Roques. 2006. Efficient approach to acyloxymethy] esters of nalidixic acid and in vitro evaluation as intra-ocular prodrugs. Bioorg. Med. Chem. 14:2569-2580.
2. Benhar, I. 2001. Biotechnological applications of phage and cell display. Biotechnol. Adv. 19:1-33.
3. Benhar, I., R. Azriel, L. Nahary, S. Shaky, Y. Berdichevsky, A. Tamarkin, and W. Weis. 2000. Highly efficient selection of phage antibodies mediated by display of antigen as Lpp-OmpA' fusions on live bacteria. J. Mol. Biol. 301:893-904.
4. Benhar, I., U. Brinkmann, K. O. Webber, and I. Pastan. 1994. Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization. Bioconjug. Chem. 5:321-326.
5. Benhar, I., and Y. Reiter. 2002. Phage display of single-chain antibodies, p. 10.19B.1-10.19B.30. In J. E. Coligan, B. E. Bierer, D. H. Margulis, E. M. Shevach, and W. Strober (ed.), Current protocols in immunology. John Wiley & Sons, Inc., New York, N.Y.
6. Berdichevsky, Y., E. Ben-Zeev, R. Lamed, and I. Benhar. 1999. Phage display of a cellulose binding domain from Clostridium thermocellum and its application as a tool for antibody engineering. J. Immunol. Methods 228:151-162.
7. Berdichevsky, Y., R. Zemel, L. Bachmatov, A. Abramovich, R. Koren, P. Sathiyamoorthy, A. Golan-Goldhirsh, R. Tur-Kaspa, and I. Benhar. 2003. A novel high throughput screening assay for HCV NS3 serine protease inhibitors. J. Virol. Methods 107:245-255.
8. Coates, A., Y. Hu, R. Bax, and C. Page. 2002. The future challenges facing the development of new antimicrobial drugs. Nat. Rev. Drug Discov. 1:895-910.
9. Djojonegoro, B. M., M. J. Benedik, and R. C. Willson. 1994. Bacteriophage surface display of an immunoglobulin-binding domain of Staphylococcus aureus protein A. Biotechnology 12:169-172.
10. Enshell-Seijffers, D., and J. M. Gershoni. 2002. Phage display selection and analysis of Ab-binding epitopes, p. 9.8.1-9.8.27. In J. E. Coligan, B. E. Bierer, D. H. Margulis, E. M. Shevach, and W. Strober (ed.), Current protocols in immunology. John Wiley & Sons, Inc., New York, N.Y.
11. Enshell-Seijffers, D., L. Smelyanski, and J. M. Gershoni. 2001. The rational design of a 'type 88' genetically stable peptide display vector in the filamentous bacteriophage fd. Nucleic Acids Res. 29:E50.
12. Farr, B. M. 2004. Prevention and control of methicillin-resistant Staphylococcus aureus infections. Curr. Opin. Infect. Dis. 17:317-322.
13. Forget, E. J., and D. Menzies. 2006. Adverse reactions to first-line antituberculosis drugs. Expert Opin. Drug Saf. 5:231-249.
14. Freeman, A., N. Cohen-Hadar, S. Abramov, R. Modai-Hod, Y. Dror, and G. Georgiou. 2004. Screening of large protein libraries by the cell immobilized on adsorbed bead approach. Biotechnol. Bioeng. 86:196-200.
15. Hunter, G. J., D. H. Rowitch, and R. N. Perham. 1987. Interactions between DNA and coat protein in the structure and assembly of filamentous bacteriophage fd. Nature 327:252-254.
16. Kaminski, M. 1969. Common and species-specific serum esterases of Equidae. I. Horse and donkey. Biochim. Biophys. Acta 191:611-620.
17. Kohler, G., and C. Milstein. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
18. Kreitman, R. J. 1999. Immunotoxins in cancer therapy. Curr. Opin. Immunol. 11:570-578.
19. Kushwaha, A., P. S. Chowdhury, K. Arora, S. Abrol, and V. K. Chaudhary. 1994. Construction and characterization of M13 bacteriophages displaying functional IgG-binding domains of staphylococcal protein A. Gene 151:45-51.
20. Liederer, B. M., and R. T. Borchardt. 2005. Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human. J. Pharm. Sci. 94:2198-2206.
21. Liu, J., M. Dehbi, G. Moeck, F. Arhin, P. Bauda, D. Bergeron, M. Callejo, V. Ferretti, N. Ha, T. Kwan, J. McCarty, R. Srikumar, D. Williams, J. J. Wu, P. Gros, J. Pelletier, and M, DuBow. 2004. Antimicrobial drug discovery through bacteriophage genomics. Nat. Biotechnol. 22:185-191.
22. Lowy, F. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339:520-532.
23. McDevitt, D., and M. Rosenberg. 2001. Exploiting genomics to discover new antibiotics. Trends Microbiol. 9:611-617.
24. 2 in relation to the presence of microbial agents, macrophage infiltrates, and transcripts of proinflammatory cytokines in human aortic tissues. Arterioscler. Thromb. Vasc. Biol. 20:751-762.
25. Merril, C. R., B. Biswas, R. Carlton, N. C. Jensen, G. J. Creed, S. Zullo, and S. Adhya. 1996. Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. USA 93:3188-3192.
26. Mikawa, Y. G., I. N. Maruyama, and S. Brenner. 1996. Surface display of proteins on bacteriophage lambda heads. J. Mol. Biol. 262:21-30.
27. Miyashita, H., Y. Karaki, M. Kikuchi, and I. Fujii. 1993. Prodrug activation via catalytic antibodies. Proc. Natl. Acad. Sci. USA 90:5337-5340.
28. Molenaar, T. J., I. Michon, S. A. de Haas, T. J. van Berkel, J. Kuiper, and E. A. Biessen. 2002. Uptake and processing of modified bacteriophage M13 in mice: implications for phage display. Virology 293:182-191.
29. Nakamura, M., K. Tsumoto, K. Ishimura, and I. Kumagai. 2001. A visualization method of filamentous phage infection and phage-derived proteins in Escherichia coli using biotinylated phages. Biochem. Biophys. Res. Commun. 289:252-256.
30. Nakamura, M., K. Tsumotob, K. Ishimuraa, and I. Kumagaib. 2002. The effect of an agglutogen on virus infection: biotinylated filamentous phages and avidin as a model. FEBS Lett. 520:77-80.
31. Nilsson, B., T. Moks, B. Jansson, L. Abrahmsen, A. Elmblad, E. Holmgren, C. Henrichson, T. A. Jones, and M. Uhlen. 1987. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng. 1:107-113.
32. Norrby, S. R., C. E. Nord, and R. Finch. 2005. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5:115-119.
33. 2 levels in patients with infections after esophageal cancer surgery. Surg. Today 35:912-918.
34. Olson, N. H., M. Gingery, F. A. Eiserling, and T. S. Baker. 2001. The structure of isometric capsids of bacteriophage T4. Virology 279:385-391.
35. Payne, D., and A. Tomasz. 2004. The challenge of antibiotic resistant bacterial pathogens: the medical need, the market and prospects for new antimicrobial agents. Curr. Opin. Microbiol. 7:435-438.
36. Projan, S. J., and D. M. Shlaes. 2004. Antibacterial drug discovery: is it all downhill from here? Clin. Microbiol. Infect. 10(Suppl. 4):18-22.
37. Sefton, A. M. 2002. Mechanisms of antimicrobial resistance: their clinical relevance in the new millennium. Drugs 62:557-566.
38. Siman-Tov, D. D., L. Navon-Perry, N. L. Haigwood, and J. M. Gershoni. 2005. Differentiation of a passive vaccine and the humoral immune response toward infection: analysis of phage displayed peptides. Vaccine 24:607-612.
39. Smith, G. P., and J. K. Scott. 1993. Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol. 217:228-257.
40. Spellberg, B., J. H. Powers, E. P. Brass, L. G. Miller, and J. E. Edwards, Jr. 2004. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38:1279-1286.
41. Trail, P. A., H. D. King, and G. M. Dubowchik. 2003. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol. Immunother. 52:328-337.
42. Turton, J. A., C. M. Andrews, A. C. Havard, and T. C. Williams. 2002. Studies on the haemotoxicity of chloramphenicol succinate in the Dunkin Hartley guinea pig. Int. J. Exp. Pathol. 83:225-238.
43. Veronese, F. M., and G. Pasut. 2005. PEGylation, successful approach to drug delivery. Drug Discov. Today 10:1451-1458.
44. White, C. A., R. L. Weaver, and A. J. Grillo-Lopez. 2001. Antibody-targeted immunotherapy for treatment of malignancy. Annu. Rev. Med. 52:125-145.
45. Yanagida, M. 1977. Molecular organization of the shell of T-even bacteriophage head. II. Arrangement of subunits in the head shell of giant phages. J. Mol. Biol. 109:515-537.
46. Zou, J., M. T. Dickerson, N. K. Owen, L. A. Landon, and S. L. Deutscher. 2004. Biodistribution of filamentous phage peptide libraries in mice. Mol. Biol. Rep. 31:121-129.